Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 2, 2006

Plexxikon and Servier Sign Cardiovascular Collaboration

  • Plexxikon and Servier announced a collaboration to discover nonpeptidic inhibitors of renin, an enzyme known to play a direct role in hypertension, renal failure, and vascular disease. “We are confident that Plexxikon’s Scaffold-Based Drug Discovery™ platform provides a unique competitive advantage to quickly identify novel, nonpeptidic renin inhibitors with attractive pharmaceutical properties,” says K. Peter Hirth, Ph.D., CEO of Plexxikon.

    Under the terms of the agreement, Plexxikon will receive an upfront payment, research funding, and potential milestone payments totaling over $100 million. In addition, Plexxikon may receive royalties on potential product sales. Servier will be responsible for clinical development and commercialization of the products and will receive an exclusive worldwide license for any renin inhibitors discovered through the collaboration in cardiovascular disease.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »